Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SURVEILLE-HPV: National, Multicenter, Open-label, Randomized, Phase II Study Evaluating HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers

NCT05582122 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT05582122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05582122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SURVEILLE-HPV: National, Multicenter, Open-label, Randomized, Phase II Study Evaluating HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal Cancers
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Recruiting
Start date
April 3, 2024
Completion date
April 1, 2031
Enrollment
420 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

oropharynx squamous cell carcinoma